文献
J-GLOBAL ID:201902255834196926
整理番号:19A2123763
抗PD-1/PD-L1阻害剤免疫療法登録試験における患者報告転帰:データのFDA分析と今後の方向【JST・京大機械翻訳】
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions
著者 (7件):
King-Kallimanis Bellinda L
(Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Howie Lynn J
(Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Roydhouse Jessica K
(Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Singh Harpreet
(Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Theoret Marc R
(Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Blumenthal Gideon M
(Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA)
,
Kluetz Paul G
(Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA)
資料名:
Clinical Trials
(Clinical Trials)
巻:
16
号:
3
ページ:
322-326
発行年:
2019年
JST資料番号:
W5192A
ISSN:
1740-7745
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)